Every 8-K that Anixa Biosciences, Inc. (ANIX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow ANIX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ANIX filings page.
Anixa Biosciences, Inc. held its 2026 annual meeting of stockholders on March 10, 2026. A total of 33,379,505 shares of common stock were entitled to vote, and 20,805,324 shares were present in person or by proxy, establishing a quorum.
Stockholders re-elected Dr. Amit Kumar, Dr. Arnold Baskies, Emily Gottschalk, and Lewis H. Titterton, Jr. as directors to serve until the 2027 annual meeting or until successors are elected and qualified. They also approved, on a non-binding, advisory basis, the Company’s executive compensation and ratified the appointment of Haskell & White LLP as independent registered public accounting firm for the fiscal year ending October 31, 2026.
The company filed as an exhibit a management presentation used at the annual meeting, which may also be used in future meetings with investors, analysts, or others.
Anixa Biosciences reported early clinical observations from its Phase 1 ovarian cancer CAR-T trial, highlighting encouraging survival in heavily pre-treated patients and a clean safety profile. Twelve women with recurrent ovarian cancer have been treated at four low-dose levels. Seven have lived beyond the expected median survival of about three to four months, including one patient who survived 28 months and several others ranging from 8 to 17 months. No dose-limiting toxicities have been seen so far, allowing regulators to approve a protocol amendment that increases the dose range from 1×10⁵–1×10⁷ CAR-positive cells/kg up to 1×10⁹ cells/kg. The next cohort will receive 1×10⁷ cells/kg with a lymphodepletion regimen to explore whether this boosts CAR-T expansion and activity in this solid tumor setting.
Anixa Biosciences, Inc. reported that it and The Cleveland Clinic Foundation presented final data from a Phase 1 clinical trial of Anixa’s investigational breast cancer vaccine. The data were shared in a presentation by Justin Johnson, Ph.D., a program manager at Cleveland Clinic and co-inventor of the vaccine technology, and were followed by a company press release. The 8-K primarily alerts investors to the completion and public disclosure of this early-stage clinical trial dataset, with additional details contained in the attached press release and presentation exhibits.